Novartis, Rochala may be the highest risk

President Donald Trump Now, on any day, prices have been worked on imported pharmaceuticals in the United States – and according to some analysts, some of the drugs can have a bigger impact on some drug manufacturers.

Trump Told reporters At the beginning of this month, their administration will start implementing a low pharmaceutical charge at the beginning of August 1 and raise the rate for about a year or 18 months. He Has been threatened To impose a 200% rate on imported drugs.

It is still unclear whether it will follow those accurate plans and rates, which makes it difficult to fully evaluate how the policy is affecting the drug manufacturer and patients. Homemade drug production operations are also increasing, as many companies have recently announced a multi-billion dollar investment in new facilities to create goodwill with the President, but it will take many years before the sites are on and on.

Some analysts have estimated the possible rate risk to different companies based on their current manufacturing network.

Abiy, Bristol Mysters Ski And Ely Lily Appeared in the “relatively good position” because their manufacturing footprints in the United States are larger than operations abroad, while Novartis And Roche TD Cowen analyst Steve Skala said in a letter on Monday.

In a letter of March, Jeffsie’s analyst Michael Yeh also called Emjin And Biogen Since the biggest contact of the charges in biotech companies, it covers. Gilliad And Vertex pharmaceuticals They may be less exposed, ”he said.

Scala said that after the implementation of the companies, at least in the first two years, the free cash flows of companies will be charged with meaningful bites. He said it was based on a conversation with an unknown expert, which is a former CFO of the Pharmaceutical Company.

The expert believes that drug manufacturers will be able to raise some drug prices, but “will be politically unstable to increase the rates completely” because patients are already in trouble to take drugs, ”he said,” he said, “he said,” he said, but he said that there is no new reason for the long -term increase in the cost of research.

Experts believe that more than 50% of pharmaceutical rates are problematic and punitive for the industry, “said Scala.

“In this case, companies need to be very aggressive in producing back to the United States, and R&D will not be able to stay away from this question,” said Scala.

In recent months, there are some pharmaceutical CEOs Slamps on imported drugsBy saying that, they will hurt R&D and can suffer less treatment on patients. Some health policy experts have already told CNBC that they could take shape Interfere with complex pharmaceutical supply chainsProbably increasing drug prices in the United States and increasing severe drug deficiency.

In a statement, Roche said that it is a “strong presence in the United States in the United States, which includes 15 research and development sites and 14 production facilities. The company recently announced the schemes to invest $ 50 billion in the United States.

Roche said, “The patient’s admission, supply chains and eventually to protect future innovation, medication and diagnostics should be exempted from the rate.” But the company says it is ready for potentially charging and confident about the ability to manage any consequences and ensures that access to its products does not interfere with and draws attention to the moving efforts such as the inventory Ments Dusstation.

Most rates mentioned by spokesperson of other companies’ spokesperson are at risk, so the requests for comment did not receive immediate response.

Scala said Abiwi, Astragenecca, Ely Lily, Merk And Fiezer Each is the largest American manufacturing network with 10 major plants.

But Abiy, Bristol Merine Skib and Eli Lily are only more well known companies in the United States abroad, he said. Abvi and Eli Lily have nine of them abroad, while Bristol Myers have two in skib.

These three companies have the highest percentage of the number of sites registered in the US Food and Drug Administration for the creation of active pharmaceutical ingredients in the United States, while Daiy’s signals, Novartis, and. Zoietus Is at least. Roche and Novo Nordis According to the note, there is also a low percentage of sites of active ingredients in the United States compared to the rest of the world.

GSK The largest is the largest drug production network abroad, with 31 major plants. But the company has said that many of them are planning to close many of the facilities, ”said Scala.

Other companies with a large number of manufacturing footprints abroad include a fiber with 27 plants, Sanofi With 16, with 14 and zautis with Elanko With 11. Merk, Roche and some drug makers including HillAccording to the note, it did not reveal how important trees are outside the United States.

He said that Ireland is a factor to remember because it seems to be a specific target of rates. Trumps are frequently Singles Ireland “To make a bait” for American drug manufacturers with decades of low corporate tax rates.

In Ireland, Abiwi and Merk have the highest FDA-registered drug production sites. Those facilities delivered to the United States or produce imported pharmaceuticals

Some manufacturers, including GSK, Novartis and Roche, do not have an iron manufacturing site registered with FDA.

The Jefferies’ arrived as a threatened companies as a result of their international tax benefits. He said there are manufacturing operations in Ireland and Singapore, which reduces the amount of payment by 6%.

Significant production of biojan is in operations in North Carolina and Switzerland. He said that the company gets 8% tax break on how to make a profit abroad.

In comparison, Vertex and Gilliad are unlikely to benefit the benefits of international taxes, he said. Vertex produces your drugs in Boston.

He further said that the presence of Gilid’s production in Ireland, mainly produces its drugs in California and sells many HIV drugs in the United States.

When the TD Cowen’s scale asked companies how they could reduce the cost, they pointed to many possible options. These include exploring alternative sources of active ingredients outside Europe or finding the production option of alternative agreements in a non -European place like American Territory Porto Rico.